home site map contact us
About Deltagen
Target Drug Discovery and Validation
Drug Discovery
Drug Metabolism
Preclinical Development
Investor Relations

Board of Directors

Constantine E. Anagnostopoulos, Ph.D.

Constantine Anagnostopoulos is Deltagen's Chairman of the Board. Dr. Anagnostopoulos is a retired corporate officer of Monsanto Company, a former managing partner of Gateway Associates, a Missouri-based venture capital firm, and the recently retired lead director of Genzyme Corporation. At Monsanto he served as Director of Research, Head of the New Enterprise Division, General Manager of a number of operating divisions and Chairman, President and CEO of Monsanto Europe-Africa-Middle East. He presently sits on the board of three biopharmaceutical companies, including Dyax Corporation. Dr. Anagnostopoulos received his Ph.D. in Organic Chemistry from Harvard University and is a graduate of the Executive Program in Business Administration of Columbia University. He has served on the Presidential Council on Innovation.

Robert J. Driscoll, J.D., Ph.D.

Robert Driscoll is Deltagen's President, Secretary and Chief Executive Officer. Dr. Driscoll served previously as Deltagen's Vice President, Intellectual Property & Legal Affairs and Associate General Counsel. Prior to joining Deltagen, Dr. Driscoll was a patent and intellectual property attorney with the law firm of Pillsbury Madison & Sutro LLP. Dr. Driscoll received his Ph.D. in Chemistry from the California Institute of Technology and his J.D. from Loyola Law School.

David J. McLachlan, M.B.A.

David McLachlan is Chairman of the Board of Skyworks Solutions, Inc., a manufacturer of analog, mixed signal and digital semiconductors for mobile communications. He also serves on the Boards of Directors of Dyax Corporation, a biotechnology company, as Chair of the Audit Committee and HearUSA, Ltd., a hearing care services company, as Lead Independent Director. He was the Executive Vice President and Chief Financial Officer of Genzyme Corporation from 1989 to 1999, and a senior adviser to Genzyme's Chairman and Chief Executive Officer until 2004. Prior to joining Genzyme, he served as Vice President and Chief Financial Officer of Adams-Russell Company, an electronic component supplier and cable television franchise owner. Mr. McLachlan is a graduate of Harvard Business School and Harvard College.

Thomas A. Penn, J.D., M.B.A.

Thomas Penn is a Partner of Meridian Venture Partners. From 1998 until 2000 Mr. Penn was a partner of Boston Millennia Partners. From 1994 until 1998, Mr. Penn served as President and Chief Executive Officer of Tektagen, Inc. Prior to joining Tektagen, Mr. Penn was President of Independence Ventures, Inc. Mr. Penn has served as President of the Pennsylvania Biotechnology Association and as Co-Chair of Pennsylvania's Technology 21 Biotechnology Network. Mr. Penn holds B.S. degrees from the Massachusetts Institute of Technology in Metallurgy and Materials Science and in Industrial Management, an M.B.A. from Stanford University, and a J.D. from the University of Pennsylvania.

William A. Scott, Ph.D.

William Scott is the former Chief Executive Officer of Physiome Sciences, where he served from 1997 to 1999. Prior to joining Physiome Sciences, Dr. Scott spent thirteen years with Bristol-Meyers Squibb where he held a number of management posts, including Senior Vice President of Exploratory and Drug Discovery Research. Dr. Scott has served on the boards of eight companies including CombiChem, Inc., and currently serves on the Boards of Atherogenics, Inc. and Avalon Pharmaceuticals, Inc. Dr. Scott holds a B.Sc. in Chemistry from the University of Illinois and a Ph.D. in Biochemistry from the California Institute of Technology. Dr. Scott is an Adjunct Professor at the Rockefeller University, where he has been affiliated since 1969.

©2010 Deltagen, Inc. All rights reserved.